Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML

NEXT STORY
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
PREV STORY
HUTCHMED Announces Agreement with NHSA for Continued Inclusion of ELUNATE® and Addition of SULANDA® in the National Reimbursement Drug List in China
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novavax to Present at the Ladenburg Thalmann 2017 Healthcare Conference

GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the ...

author_avatar
NASDAQ Market News

Cesca Announces Closing of $5.5 Million Public Offering

RANCHO CORDOVA, Calif., May 18, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a ...

author_avatar
NASDAQ Market News

VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018

Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study ...

author_avatar
NASDAQ Market News